The estimated Net Worth of Real Estate Equities, Inc.A... is at least $32.6 Million dollars as of 4 June 2024. Real A owns over 300,000 units of Applied Therapeutics stock worth over $30,504,951 and over the last 6 years Real sold APLT stock worth over $2,049,026.
Real has made over 4 trades of the Applied Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Real sold 300,000 units of APLT stock worth $1,269,000 on 4 June 2024.
The largest trade Real's ever made was buying 3,500,000 units of Applied Therapeutics stock on 27 June 2022 worth over $3,500,000. On average, Real trades about 728,963 units every 264 days since 2019. As of 4 June 2024 Real still owns at least 5,855,077 units of Applied Therapeutics stock.
You can see the complete history of Real A stock trades at the bottom of the page.
Over the last 6 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus und Shoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Applied Therapeutics executives and other stock owners filed with the SEC include: